5.10 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||4.55 x 100|
|Ask||5.30 x 1200|
|Day's Range||5.05 - 5.15|
|52 Week Range||3.60 - 6.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.20|
SUNNYVALE, Calif., April 17, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.
Accuray Incorporated (ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.
SUNNYVALE, Calif. , April 9, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2018 on Monday, April 30, 2018 after the market close, following ...
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
SUNNYVALE, Calif., March 28, 2018 /PRNewswire/ -- Personalized, precise, radiation treatments will soon be available to more cancer patients in India. Accuray Incorporated (ARAY) announced today that the company has signed an agreement with the Apollo Hospitals Group in Chennai and New Delhi, India, for the acquisition of two Radixact® Systems, radiation therapy devices that have been proven to deliver highly accurate treatments for a broad range of tumors anywhere in the body. The installation of these systems, one replacing a conventional linear accelerator and the other in a new vault, will expand access to state-of-the-art cancer treatment technology for the people of India.
SUNNYVALE, Calif. and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife® System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. "At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC.
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.
To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.
Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.
Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SUNNYVALE, Calif. , Feb. 15, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will present at the 2018 RBC Capital Markets Global Healthcare Conference at the Lotte ...
NEW YORK, Feb. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accuray ...
SUNNYVALE, Calif., Feb. 5, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it has retired all February 2018 convertible notes, including $13 million aggregate principal amount of its 3.50% convertible senior notes and $27 million aggregate principal amount of its 3.50% Series A convertible senior notes both due February 1, 2018. Accuray successfully entered into exchange agreements with the holders of the 3.50% convertible senior notes allowing the Company to settle the $13 million outstanding principal amount and accrued interest in cash and approximately 0.3 million shares of its common stock. After giving effect to the settlement of the exchange agreements, no 3.50% convertible senior notes will remain outstanding.
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.